Protocol Ledger

NCT03947255 · Phase II · TERMINATED

A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma

Interventional Phase II clinical trial protocol NCT03947255 sponsored by Pfizer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-10-28 Enrollment: 12 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03947255
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)12 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03947255
Protocol FieldVerified Registry Value
NCT IdentifierNCT03947255
Consolidated Lead SponsorPfizer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment12 participants (ACTUAL)
Registered Start Date2019-10-28
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03947255
Hospital Research SiteLocationSite Profile
Norton Cancer InstituteLouisville, KYOpen Hospital Dossier ->
University of MarylandBaltimore, MDOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI